FAA grounds helicopter company involved in deadly New York crash
FAA grounds helicopter company involved in deadly New York crash The crash revived safety concerns about the aerial tourism industry. Helicopter tours in New York have been controversial and in some cases deadly.
Show Caption
Hide Caption
Helicopter crash in the Hudson revives call for more regulations
Jersey City Mayor Steven Fulop is asking the FAA to restrict tourism flights citing an already crowded airspace along the Hudson River.
The Federal Aviation Administration issued an emergency order grounding the helicopter tour company involved in the deadly crash in New York as federal officials investigate the tragedy.
Jason Costello, then-director of operations at New York Helicopter Charter Inc., agreed to shut down operations on April 13 after a Bell 206 helicopter the company operated plunged into the Hudson River, killing six people, according to the FAA. But just sixteen minutes after Costello confirmed this, company CEO Michael Roth fired Costello and told the FAA via email that he did not authorize the halt and that Costello was no longer his employee.
'The immediate firing of the Director of Operations raise serious safety concerns because it appears Mr. Roth retaliated against Mr. Costello for making the safety decision to cease operations during the investigation," FAA officials said in the emergency order, adding that the company no longer has a qualified person serving as director of operations.
Roth and someone who answered the phone at New York Helicopter Tours declined to comment when reached by USA TODAY. Attempts to contact Costello were unsuccessful.
What happened during the crash?
The helicopter, which is owned by Louisiana-based company Meridian Helicopters LLC, took off at about 3 p.m. April 10 from a heliport in downtown Manhattan for an aerial tour of the city, authorities said. The helicopter crashed about 15 minutes later near Jersey City, New Jersey, officials said.
Video of the crash captured the helicopter and a detached rotor descending to the water. The pilot, Seankese Johnson, and passengers Agustin Escobar, his wife and their three children were killed.
The crash revived safety concerns about the aerial tourism industry. Helicopter tours in New York have been controversial and in some cases deadly, USA TODAY reported.
Records obtained by USA TODAY showed that New York Helicopter Charter Inc. was involved in two earlier safety incidents. The downed helicopter's last major inspection was on March 1, and it completed seven tour flights before the crash, according to the National Transportation Safety Board.
Crash under federal investigation
The FAA is conducting a review, known as a Certificate Holder Evaluation Program, that will determine whether the operator complies with regulations, effectively manages safety, and identifies hazards and risks, Acting Administrator Chris Rocheleau said April 14 on X.
If the company does not immediately surrender its air-carrier certificate amid the investigation, it could face "further legal enforcement action, including a civil penalty of up to $17,062 a day for each day it fails to surrender the certificate," according to the order.
The NTSB also is investigating the crash. Investigators with the agency have met with representatives from New York Helicopter Charter Inc. to review operational records, policies and procedures, safety management systems and the pilot's experience, the agency said April 12.
The cause of the crash has not yet been determined. Aviation experts have told USA TODAY that footage appears to indicate the helicopter's rotor experienced a catastrophic failure.
Contributed: Christopher Cann
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
28 minutes ago
- CNBC
Small caps are breaking out just in time for a summer rally, market watchers say
The summer might belong to the small caps, which are finally showing signs of breaking out. The S & P 500 is back above 6,000, after touching the psychological level at the end of last week in what could be a bullish signal for stocks. But on the Street, market watchers are more interested in what's going on with the Russell 2000 , after its rally last week. The small-cap index jumped more than 3% in June. "We think this could be setting up for 'smallcap summer,'" Jonathan Krinsky, chief market technician at BTIG, wrote Sunday. JC O'Hara, chief technical strategist at Roth, echoed this thought in a Sunday note titled "The Summer of Small?" "We have been closely watching Small Caps as the Russell 2000 started to form an accumulation pattern several weeks ago," he said. "Last week, price was finally able to break out. This sort of formation historically has further upside." .RUT YTD mountain Russell 2000, year to date The Russell 2000 has been punished in 2025, falling roughly 10% in just the first quarter after rising recession fears hurt an asset class more sensitive to economic cycles. Many investors had been excited about the group heading into the year, expecting President Donald Trump's pro-business policies would be especially beneficial to smaller companies, before tariff uncertainty knocked that outlook. However, small caps are starting to look attractive as more of the market moves on from trade headlines, and investors look forward instead to more constructive forces such as interest rate cuts. The Russell 2000 remains in a correction, more than 13% off its recent peak. If the index can clear resistance at its 200-day moving average, breadth, which has remained poor, has plenty of room to expand. "Have universally unloved Small Caps become 'So Bad, They're Good'?" Julian Emanuel, senior managing director leading the equity, derivatives and quantitative strategy team at Evercore ISI, asked in a Sunday note. "Tactically, cratered sentiment intersects with favorable June seasonality." The strategist, who recommended buying the iShares Russell 2000 ETF (IWM) , noted the seasonal and historical trends are in favor of the asset group. In the five other comparable instances when small caps suffered similar declines through the January to May period, they came roaring back in June, he said. The S & P 500 could benefit from a rally in small caps as well. An improvement in breadth in the Russell 2000 that's suggestive of a risk-on market could mean the recent gains in the larger-cap index are similarly sustainable. Ari Wald, head of technical analysis at Oppenheimer, wrote Saturday that he would like to see more than 60% of Russell 3000 stocks to trade above their 200-day average, up from their current 38%. He wrote: "The Russell 2000 would be a likely catalyst for broader market activity, and a Russell breakout above 2,180 (200-day average) should help ignite this untapped firepower." The Russell 2000 was last around 2,140. Elsewhere, Piper Sandler's Craig W. Johnson pointed out that the Russell 2000, which has gone three straight years without making a new high, has never gone four years without one. He said: "We believe small caps are overdue and have room to run back toward their prior highs."
Yahoo
40 minutes ago
- Yahoo
Hologic Climbs 13% in a Month: How Should You Play the Stock?
After lagging for months, Hologic HOLX has picked up momentum in recent weeks. Shares of the Marlborough, MA-based company have climbed 13.3% over the past month, higher than the industry and the broader Medical sector's gains of 2.4% and 3.4%, respectively. The current price is now 23.9% above the 52-week low of $51.90, boosted in part by reports that Hologic declined a private takeover bid from TPG and Blackstone. HOLX has also managed to outperform two of its key competitors — Exact Sciences EXAS and Becton, Dickinson and Company BDX, or BD, in the same time frame. Image Source: Zacks Investment Research Investor sentiment was already subdued after the release of the company's fiscal 2025 second-quarter earnings in early May. Hologic met adjusted EPS expectations with a modest revenue beat but revised its annual outlook due to the growing tariff impact from China and Costa Rica, funding cuts affecting the Africa business, and a soft capital equipment market. In contrast, Exact Sciences anticipates 'little to no tariff impact' due to all domestic operations, while BD expects $90 million in tariff expenses for fiscal 2025, mostly from China imports. That said, let's explore what might be driving Hologic's recent rally. On May 27, HOLX shares rose nearly 15% following a report from the Financial Times that the company turned down a non-binding offer from private equity (PE) firms TPG and Blackstone. The deal was valued at up to $16.7 billion, including debt. These firms, known for their solid history of healthcare investments, teamed up last year to explore a potential acquisition of Bausch + Lomb, which eventually did not happen. The proposed takeover bid of Hologic would have been one of the largest leveraged buyouts of the year, valuing the company's shares between $70 and $72 — roughly a 30% premium to the May 23 closing price of $54.28. The report also stated that there is a possibility the deal discussions might resume, according to people with knowledge of the matter. Hologic has attracted buyers' attention for a while now. Of late, the take-private activities by PE firms have seen a sharp increase, such as Sycamore Partners' $24 billion deal for Walgreens Boots Alliance, Thoma Bravo's $10.6 billion acquisition of Boeing's software unit, and 3G Capital's $10.5 billion deal for Skechers. Nonetheless, the high premium in the offer signals strong confidence in Hologic's growth potential. The company presented new data showing the significant clinical impact of the Breast Cancer Index ('BCI') test at the 2025 American Society of Clinical Oncology Annual Meeting held on June 2. The molecular, gene expression-based test from Hologic's subsidiary, Biotheranostics, has been a key growth driver in the molecular diagnostics business over the past few quarters. The latest data from the prospective, multi-center BCI Registry Study highlights how this genomic test plays a critical role in guiding extended endocrine therapy decisions for women with early-stage, hormone receptor-positive (HR+) breast cancer. With more than 2,800 patients involved, the study found that BCI testing led to a change in treatment recommendations for about four in 10 cases. Additionally, physicians' confidence in their treatment recommendations got a boost, while patients felt comfortable in their decisions, citing fewer concerns about cost, drug safety and preference related to extended endocrine therapy benefits. Hologic looks attractive from a valuation standpoint. The stock has been trading at a price-to-sales (P/S) of 3.40X over the past five years compared to its median of 4.33X and the industry average of 4.16X. It has a Value Score of B at present. Image Source: Zacks Investment Research Meanwhile, both Exact Sciences and BD are trading at a premium to their industry average, with P/S of 3.16X and 2.20X respectively. Molecular Diagnostics assays are likely to continue to be the principal revenue-generating component in the Diagnostics division. As Hologic drives awareness and reimbursement in the highly unpenetrated U.S. vaginitis market, the BV CV/TV assay is poised to see a strong uptake. Aligning with its long-term revenue diversification strategy, the company's Breast Health service revenues are now larger and growing more steadily than the gantry business. The 2024 acquisition of Endomagnetics boosted the Interventional Breast portfolio with market-leading product lines and strong R&D capabilities for further portfolio expansion. The upcoming launch of innovations like the Envision Mammography Platform is likely to gain a favorable reception. In Surgical, Myosure's strong international growth points to the high demand for minimally invasive options for treating uterine polyps and fibroids. Hologic continues to expand this division both organically and through acquisitions such as Gynsesonics, leveraging its established sales channel. Further, the company is building capabilities to grow internationally on a consistent basis by going directly into more geographies and businesses. A consistently strong profitability has contributed to a fortress balance sheet over time, allowing Hologic to execute on both tuck-in M&A and share repurchases. Based on short-term price targets offered by 15 analysts, the Zacks average price target is $68.13 per share. The average suggests a potential 8.02% upside from last Friday's closing price. Image Source: Zacks Investment Research Hologic has some promising catalysts for long-term expansion, supported by an attractive valuation relative to its industry. However, despite outperforming peers over the past month, the Zacks Rank #3 (Hold) stock is navigating a turbulent macroeconomic landscape, which is expected to weigh on its financial performance in the near term. Hence, those eyeing HOLX may find it wise to wait for a better entry point, while current shareholders should retain their position. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
41 minutes ago
- Yahoo
Ecksand Awarded the Canadian National Mark, a Rare Honour in Fine Jewellery
Toronto, Ontario--(Newsfile Corp. - June 9, 2025) - Ecksand, the Montreal-based fine jewellery maison known for its ethical Canadian-made craftsmanship, has officially been awarded the Canadian National Mark, a prestigious designation granted by the Commissioner of Competition. Under the Precious Metals Marking Act, this government-regulated hallmark confirms that each Ecksand piece is made in Canada, from gemstone sourcing to final polish, under strict standards of quality and traceability. With only 108 National Mark certificates issued to date, and estimates showing that even fewer brands have been able to maintain this standard in recent years, this award is a rare distinction in the jewellery world, placing Ecksand among an elite group of brands recognized for genuine Canadian production. Unlike typical "Made in Canada" labels, the National Mark demands verified local manufacturing, traceable materials and compliance with stringent purity and quality standards, making it one of the highest acknowledgements of authenticity and trust in a brand. For Ecksand, this recognition is more than a stamp. It is a powerful affirmation of the maison's commitment to transparency, ethical sourcing and artisanal integrity. In an industry where vague origin claims are common, the Canadian National Mark sets Ecksand apart with certified accountability. "At Ecksand, sustainability isn't just a responsibility, it's part of our design and craftsmanship philosophy. Every detail, from our ethical noble materials to the thoughtful sculpting of each piece, is guided by the belief that beauty should last," says Erica Bianchini, Ecksand's Creative Director. "The Canadian National Mark affirms what we've always stood for: transparency, artistry and craftsmanship rooted here at home." Founded in 2009, Ecksand has built a reputation for creating fine jewellery with purpose. With a fully vertical, green atelier in Montreal, the maison oversees every step of its jewellery-making process in-house, producing heirloom-quality engagement rings and handcrafted bracelets, necklaces and earrings. Each piece is a reflection of Ecksand's artisanal skill and environmental care. Not only does this ensure full creative control, it also guarantees a transparent supply chain and sustainable practices that align with the values of today's discerning buyer. The Canadian National Mark now serves as formal recognition of these long-standing commitments and reinforces the maison's mission to deliver responsible luxury that lasts for generations. Explore Ecksand's certified collections and learn more about the Canadian National Mark at About: Founded in 2009, Ecksand is a French-Canadian fine jewellery Maison renowned for its iconic collections and sustainable practices. Headquartered in Montreal, the brand is led by Creative Director Erica Bianchini, whose creative vision guides a passionate team dedicated to crafting high-end jewellery that combines responsibly sourced materials with artisanal manufacturing. This year, Ecksand was officially awarded the Canadian National Mark—a rare hallmark granted by the Commissioner of Competition under the Precious Metals Marking Act. With only a handful of National Mark certificates issued to date, this prestigious designation confirms that every Ecksand piece is a Product of Canada, made under strict standards of traceability and quality. The award affirms the Maison's long-standing commitment to transparency, ethical sourcing, and exceptional Canadian craftsmanship. As one of the leading Canadian jewelers in sustainable luxury, Ecksand prides itself on its eco-conscious ethos. Every creation begins with Erica Bianchini's thoughtful design vision, paired with precise engineering to ensure exceptional quality. From there, noble materials—such as recycled gold and traceable natural gemstones—are brought to life through meticulous craftsmanship. Each ring spends at least six hours in the hands of Ecksand's skilled artisans, undergoing a multi-step process rooted in time-honoured techniques. Ecksand doesn't count the hours it takes to perfect a piece—it trusts the expert workmanship established in its state-of-the-art workshop. Every jewel is handcrafted in Ecksand's fully green, vertically integrated Montreal atelier—an environment optimized for minimal environmental impact. There, each piece undergoes final polishing, inspection, and refinement to meet the Maison's highest standards. With a focus on iconic design, Ecksand offers a curated selection of bridal and fine jewelry, including signature collections such as The Mark, Duel, Arctic Dragon, and Starlight. Featuring handcrafted engagement rings, diamond earrings, and one-of-a-kind gemstone pieces that honour the Maison's French-Canadian artisanal heritage, Ecksand continues to champion its mission of responsible luxury made to last for generations. This commitment has brought Ecksand to red carpets from the Oscars to New York Fashion Week, as the Maison's timeless artistry becomes a staple among international celebrities. Ecksand is available online and ships internationally. The brand also welcomes clients at its Montreal and Toronto boutiques, where personalized consultations can be booked for a tailored shopping experience. Alanna Arsenault alanna@ To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
